AstraZeneca (AZN)
(Delayed Data from NSDQ)
$75.17 USD
+0.14 (0.19%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $75.17 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
- YR Estimate
- 12/31/2023
- 12/31/2022
- 12/31/2021
- 12/31/2020
- 12/31/2019
- Revenue - Line of Business (LOBR)
- Product Sales: Oncology: Tagrisso
- 5,799.00
- 5,444.00
- 5,015.00
- 4,328.00
- 3,189.00
- Revenue - Line of Business (LOBR)
- Product Sales: Oncology: Imfinzi
- 4,237.00
- 2,784.00
- 2,412.00
- 2,042.00
- 1,469.00
- Revenue - Line of Business (LOBR)
- Product Sales: Oncology: Lynparza
- 2,811.00
- 2,638.00
- 2,348.00
- 1,776.00
- 1,198.00
- Revenue - Line of Business (LOBR)
- Product Sales: Oncology: Calquence
- 2,514.00
- 2,057.00
- 1,238.00
- 522.00
- 164.00
- Revenue - Line of Business (LOBR)
- Product Sales: Oncology: Zoladex
- 952.00
- 927.00
- 948.00
- 888.00
- 813.00
- Revenue - Line of Business (LOBR)
- Product Sales: Oncology: Faslodex
- 297.00
- 334.00
- 431.00
- 580.00
- 892.00
- Revenue - Line of Business (LOBR)
- Product Sales: Other: Synagis
- 546.00
- 578.00
- 410.00
- 372.00
- 358.00
- Revenue - Line of Business (LOBR)
- Product Sales: Other: Nexium
- 945.00
- 1,285.00
- 1,326.00
- 1,492.00
- 1,483.00
- Revenue - Line of Business (LOBR)
- Product Sales: CVRM: Crestor
- 1,107.00
- 1,048.00
- 1,096.00
- 1,180.00
- 1,278.00
- Revenue - Line of Business (LOBR)
- Product Sales: CVRM: Seloken/Toprol-XL
- 640.00
- 862.00
- 951.00
- 821.00
- 760.00
- Revenue - Line of Business (LOBR)
- Product Sales: Other Medicines: Other: Emerging Markets
- 153.00
- 220.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Other Medicines: Emerging Markets
- 731.00
- 788.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Oncology: Tagrisso: Established RoW
- 782.00
- 847.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Oncology: Imfinzi: Established RoW
- 802.00
- 401.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Oncology: Lynparza: Established RoW
- 281.00
- 269.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Oncology: Calquence: Established RoW
- 108.00
- 69.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Oncology: Zoladex: Established RoW
- 118.00
- 122.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Oncology: Faslodex: Established RoW
- 96.00
- 103.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Oncology: Others: Established RoW
- 47.00
- 10.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Oncology: Established RoW Total
- 2,266.00
- 1,884.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: CVRM: Andexxa: Established RoW
- 45.00
- 32.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Oncology: Orpathys: Emerging Markets
- 44.00
- 33.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Oncology: Zoladex: Emerging Markets
- 687.00
- 657.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Oncology: Faslodex: Emerging Markets
- 142.00
- 159.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Oncology: Others: Emerging Markets
- 165.00
- 27.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Oncology: Emerging Markets Total
- 3,828.00
- 3,537.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: CVRM: Farxiga: Emerging Markets
- 2,211.00
- 1,665.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: CVRM: Brilinta: Emerging Markets
- 285.00
- 286.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: CVRM: Lokelma: Emerging Markets
- 50.00
- 20.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: CVRM: Roxadustat: Emerging Markets
- 271.00
- 197.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: CVRM: Crestor: Emerging Markets
- 862.00
- 794.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: CVRM: Bydureon
- 163.00
- 280.00
- 385.00
- 448.00
- 549.00
- Revenue - Line of Business (LOBR)
- Product Sales: Respiratory: Fasenra
- 1,553.00
- 1,396.00
- 1,258.00
- 949.00
- 704.00
- Revenue - Line of Business (LOBR)
- Product Sales: CVRM: Brilinta
- 1,324.00
- 1,358.00
- 1,472.00
- 1,593.00
- 1,581.00
- Revenue - Line of Business (LOBR)
- Product Sales: CVRM: Onglyza
- 227.00
- 257.00
- 360.00
- 470.00
- 527.00
- Revenue - Line of Business (LOBR)
- Product Sales: CVRM: Farxiga
- 5,963.00
- 4,381.00
- 3,000.00
- 1,959.00
- 1,543.00
- Revenue - Line of Business (LOBR)
- Breztri: Total World Sales
- 677.00
- 398.00
- 203.00
- 28.00
- 2.00
- Revenue - Line of Business (LOBR)
- Product Sales: CVRM: Lokelma
- 412.00
- 289.00
- 175.00
- 76.00
- 14.00
- Revenue - Line of Business (LOBR)
- Product Sales: Oncology: Koselugo: Total World Sales
- 331.00
- 208.00
- 108.00
- 38.00
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Oncology
- 17,145.00
- 14,631.00
- 13,048.00
- 10,850.00
- 8,667.00
- Revenue - Line of Business (LOBR)
- Product Sales: CVRM(Cardiovascular, Renal & Metabolic)
- 10,585.00
- 9,188.00
- 8,020.00
- 7,096.00
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Respiratory
- 6,107.00
- 5,765.00
- 6,034.00
- 5,357.00
- --
- Revenue - Line of Business (LOBR)
- Product Sales: CVRM: Roxadustat
- 271.00
- 197.00
- 174.00
- 30.00
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Vaccines & Immune Therapies: FluMist / Fluenz: Total
- 216.00
- 175.00
- 253.00
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Oncology: Others
- 224.00
- 44.00
- 50.00
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: CVRM: Other
- 296.00
- 366.00
- 196.00
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Respiratory: Other
- 324.00
- 421.00
- 594.00
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Oncology: Enhertu
- 261.00
- 79.00
- 17.00
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Oncology: Tagrisso: Emerging Markets
- 1,621.00
- 1,567.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Oncology: Imfinzi: Emerging Markets
- 360.00
- 287.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Oncology: Lynparza: Emerging Markets
- 542.00
- 488.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Oncology: Calquence: Emerging Markets
- 98.00
- 45.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Oncology: Enhertu: Emerging Markets
- 169.00
- 51.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: CVRM: Established RoW Total
- 744.00
- 684.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Other Medicines: Other: Total
- 231.00
- 340.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Other Medicines: Established RoW
- 207.00
- 570.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Other Medicines: Total
- 1,176.00
- 1,625.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Alliance Revenue
- 1,428.00
- --
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Oncology: Orpathys: Total
- 44.00
- 33.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: CVRM: Andexxa: Total
- 182.00
- 150.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Rare Disease: Soliris: Total
- 3,145.00
- 3,762.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Rare Disease: Soliris: Established RoW
- 317.00
- 476.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Rare Disease: Strensiq: Total
- 1,152.00
- 958.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Rare Disease: Strensiq: Established RoW
- 86.00
- 76.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Rare Disease: Koselugo: Established RoW
- 24.00
- 0.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Rare Disease: Kanuma: Established RoW
- 8.00
- 8.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Rare Disease: Kanuma: Total
- 171.00
- 160.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Rare Disease: Established RoW
- 911.00
- 870.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Other Medicines: Nexium: Established RoW
- 199.00
- 551.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Other Medicines: Other: Established RoW
- 8.00
- 19.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Daliresp/Daxas: Total World Sales
- 54.00
- 189.00
- 227.00
- 217.00
- 215.00
- Revenue - Line of Business (LOBR)
- Product Sales: Respiratory: Symbicort
- 2,362.00
- 2,538.00
- 2,728.00
- 2,721.00
- 2,495.00
- Revenue - Line of Business (LOBR)
- Product Sales: Respiratory: Pulmicort
- 713.00
- 645.00
- 962.00
- 996.00
- 1,466.00
- Revenue - Line of Business (LOBR)
- Product Sales: Respiratory: Bevespi
- 58.00
- 58.00
- 54.00
- 48.00
- 42.00
- Revenue - Line of Business (LOBR)
- Product Sales: CVRM: Seloken/Toprol-XL: Emerging Markets
- 621.00
- 839.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: CVRM: Onglyza: Emerging Markets
- 131.00
- 121.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: CVRM: Bydureon: Emerging Markets
- 3.00
- 3.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: CVRM: Others: Emerging Markets
- 152.00
- 194.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: CVRM: Emerging Markets Total
- 4,586.00
- 4,119.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Rare Disease: Soliris: Emerging Markets
- 424.00
- 301.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Rare Disease: Strensiq: Emerging Markets
- 40.00
- 35.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Rare Disease: Koselugo: Emerging Markets
- 59.00
- 26.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Rare Disease: Kanuma: Emerging Markets
- 29.00
- 31.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Rare Disease: Emerging Markets
- 623.00
- 431.00
- --
- --
- --
- Revenue - Line of Business (LOBR)
- Product Sales: Other Medicines: Nexium: Emerging Markets
- 578.00
- 568.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Product Sales: Oncology: Tagrisso: Europe
- 1,120.00
- 1,023.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Product Sales: Oncology: Imfinzi: Europe
- 758.00
- 544.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Product Sales: Oncology: Lynparza: Europe
- 734.00
- 655.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Product Sales: Oncology: Calquence: Europe
- 493.00
- 286.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Product Sales: Oncology: Enhertu: Europe
- 60.00
- 21.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Product Sales: Oncology: Enhertu: Established RoW
- 32.00
- 7.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Product Sales: Oncology: Zoladex: Europe
- 133.00
- 133.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Product Sales: Oncology: Faslodex: Europe
- 28.00
- 55.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Product Sales: Oncology: Others: Europe
- 6.00
- 6.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Product Sales: Other Medicines: Europe
- 105.00
- 123.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Product Sales: CVRM: Farxiga: Established RoW
- 420.00
- 348.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Daliresp/Daxas: Europe Sales
- 8.00
- --
- --
- --
- --
- Revenue - Geographic (GEOR)
- Symbicort: U.S. Sales
- 726.00
- 973.00
- 1,065.00
- 1,022.00
- 829.00
- Revenue - Geographic (GEOR)
- Pulmicort: U.S. Sales
- 28.00
- 65.00
- 72.00
- 71.00
- 110.00
- Revenue - Geographic (GEOR)
- Bevespi: U.S. Sales
- 34.00
- 42.00
- 39.00
- 44.00
- 42.00
- Revenue - Geographic (GEOR)
- Crestor: U.S. Sales
- 55.00
- 65.00
- 80.00
- 92.00
- 104.00
- Revenue - Geographic (GEOR)
- Product Sales: CVRM: Crestor: Europe
- 52.00
- 41.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Product Sales: CVRM: Seloken/Toprol-XL: Europe
- 11.00
- 14.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Product Sales: CVRM: Onglyza: Europe
- 32.00
- 38.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Product Sales: CVRM: Bydureon: Europe
- 27.00
- 35.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Product Sales: CVRM: Others: Europe
- 109.00
- 128.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Product Sales: CVRM: Europe Total
- 2,503.00
- 1,906.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Product Sales: Rare Disease: Soliris: Europe
- 670.00
- 805.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Product Sales: Other Medicines: Nexium: Europe
- 53.00
- 46.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Product Sales: Other Medicines: Other: Europe
- 52.00
- 77.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Product Sales: Rare Disease: Europe
- 1,529.00
- 1,428.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Product Sales: CVRM: Crestor: Established RoW
- 138.00
- 148.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Product Sales: CVRM: Seloken/Toprol-XL: Established RoW
- 7.00
- 9.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Product Sales: CVRM: Onglyza: Established RoW
- 15.00
- 22.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Product Sales: CVRM: Others: Established RoW
- 5.00
- 10.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Product Sales: CVRM: Andexxa: U.S.
- 75.00
- 77.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Product Sales: CVRM: Others: U.S. Sales
- 30.00
- 34.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Product Sales: Rare Disease: Soliris: U.S.
- 1,734.00
- 2,180.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Product Sales: Rare Disease: Kanuma: U.S.
- 85.00
- 77.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Product Sales: Other Medicines: Other: U.S.
- 18.00
- 24.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Product Sales: Other Medicines: U.S.
- 133.00
- 144.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Product Sales: Rare Disease: Strensiq: Europe
- 89.00
- 78.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Product Sales: Rare Disease: Koselugo: Europe
- 53.00
- 20.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Product Sales: Rare Disease: Kanuma: Europe
- 49.00
- 44.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Daliresp/Daxas: U.S. Sales
- 42.00
- 176.00
- 207.00
- 190.00
- 184.00
- Revenue - Geographic (GEOR)
- Imfinzi: U.S. Sales
- 2,317.00
- 1,552.00
- 1,780.00
- 1,185.00
- 1,041.00
- Revenue - Geographic (GEOR)
- Calquence: U.S. Sales
- 1,815.00
- 1,657.00
- 1,089.00
- 511.00
- 162.00
- Revenue - Geographic (GEOR)
- Farxiga: U.S. Sales
- 1,451.00
- 1,071.00
- 732.00
- 569.00
- 537.00
- Revenue - Geographic (GEOR)
- Lokelma: U.S. Sales
- 214.00
- 170.00
- 115.00
- 57.00
- 13.00
- Revenue - Geographic (GEOR)
- Product Sales: Rare Disease: Koselugo: U.S.
- 195.00
- 162.00
- 104.00
- 38.00
- --
- Revenue - Geographic (GEOR)
- Oncology: U.S. Sales
- 7,719.00
- 6,484.00
- 5,359.00
- 4,250.00
- 3,449.00
- Revenue - Geographic (GEOR)
- BioPharmaceuticals: Total CVRM: U.S. Sales
- 2,752.00
- 2,479.00
- 2,124.00
- 2,083.00
- --
- Revenue - Geographic (GEOR)
- BioPharmaceuticals: Total Respiratory & Immunology: U.S. Sales
- 2,547.00
- 2,655.00
- 2,404.00
- 1,941.00
- --
- Revenue - Geographic (GEOR)
- Total Product Sales: Total World Sales
- 43,789.00
- 42,998.00
- 36,541.00
- 25,890.00
- 23,565.00
- Revenue - Geographic (GEOR)
- Total Product Sales: U.S. Sales
- 17,961.00
- 17,254.00
- 12,000.00
- 8,638.00
- 7,747.00
- Revenue - Geographic (GEOR)
- Product Sales: Oncology: Europe Total
- 3,332.00
- 2,726.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Product Sales: CVRM: Farxiga: Europe
- 1,881.00
- 1,297.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Product Sales: CVRM: Brilinta: Europe
- 271.00
- 282.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Product Sales: CVRM: Lokelma: Europe
- 58.00
- 30.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Product Sales: CVRM: Andexxa: Europe
- 62.00
- 41.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Product Sales: CVRM: Brilinta: Established RoW
- 24.00
- 46.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Product Sales: CVRM: Lokelma: Established RoW
- 90.00
- 69.00
- --
- --
- --
- Revenue - Geographic (GEOR)
- Bydureon: U.S. Sales
- 133.00
- 242.00
- 321.00
- 382.00
- 459.00
- Revenue - Geographic (GEOR)
- Zoladex: U.S. Sales
- 14.00
- 15.00
- 13.00
- 5.00
- 7.00
- Revenue - Geographic (GEOR)
- Faslodex: U.S. Sales
- 31.00
- 17.00
- 30.00
- 55.00
- 328.00
- Revenue - Geographic (GEOR)
- Tagrisso: U.S. Sales
- 2,276.00
- 2,007.00
- 1,780.00
- 1,566.00
- 1,268.00
- Revenue - Geographic (GEOR)
- Product Sales: Other Medicines: Nexium-US
- 115.00
- 120.00
- 128.00
- 169.00
- 218.00
- Revenue - Geographic (GEOR)
- Fasenra: U.S. Sales
- 992.00
- 906.00
- 790.00
- 603.00
- 482.00
- Revenue - Geographic (GEOR)
- Brilinta: U.S. Sales
- 744.00
- 744.00
- 735.00
- 732.00
- 710.00
- Revenue - Geographic (GEOR)
- Onglyza: U.S. Sales
- 49.00
- 76.00
- 88.00
- 166.00
- 230.00
- Revenue - Geographic (GEOR)
- Lynparza: U.S. Sales
- 1,254.00
- 1,226.00
- 1,087.00
- 876.00
- 626.00